Compare Novavax Inc (NVAX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Zillow Group Inc Class A — how do they compare? Novavax Inc trades at $12.69 (market cap $1.82B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Zillow Group Inc Class A is far larger — about 3.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Zillow Group Inc Class A for 86 Days on average.
| NVAX | ZG | |
|---|---|---|
Market Cap | $1.82B | $6.59B |
Volume | 6,198,505 | 1,361,381 |
Sector | Health | Media |
52-Week High | $12.56 | $74.58 |
52-Week Low | $6.22 | $27.70 |
Typical Hold Time | 59 Days | 86 Days |
Enterprise Value | $1.39B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Zillow Group (ZG) trades at $29.87, up 6.79% on the day, showing strong momentum despite mixed technical signals. The company has demonstrated improved financial performance with revenue growth from $2.2B in 2024 to $2.6B in 2025 and achieving profitability with $23M net income after three years of losses. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though Q4 2025 missed expectations. Analyst consensus remains divided with a Hold rating but offers significant upside potential with a $48.87 price target.
The outlook for ZG appears cautiously optimistic with fundamental improvement offset by housing market headwinds. Investment opportunity lies in the company's transition to profitability and market share gains in digital real estate, while risks include interest rate sensitivity, competitive pressures from Compass, and ongoing housing affordability challenges that could impact transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
